Ignacio
Matos García
Consultor Médico
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (8)
2021
-
A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors
Radiology, Vol. 299, Núm. 1, pp. 109-119
-
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
European Journal of Cancer, Vol. 155, pp. 168-178
2020
-
Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria
Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855
-
Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial
Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317
2019
-
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials
Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471
2018
-
Early evolutionary divergence between papillary and anaplastic thyroid cancers
Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460
-
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer
Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629
-
The safety of ramucirumab for the treatment of colorectal cancer
Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951